Micolamina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micolamina

This section provides a factual, authoritative definition of Micolamina (Ciclopirox), establishing its identity, composition, and general purpose without detailing specific clinical uses, dosages, or administration instructions.

Property Description
Active ingredient Ciclopirox (or Ciclopirox olamine)
Form Topical Preparations (Lacquer, Cream, Gel, Shampoo)
Pharmacological class Antifungal Agent (Hydroxypyridone class)
Common use Resolution of superficial biological intrusions
Origin Synthetic

What Type of Medicine is Micolamina?

Micolamina is a pharmaceutical preparation containing the active ingredient Ciclopirox, which is a synthetic, broad-spectrum Antifungal Agent. This compound belongs to the unique Hydroxypyridone chemical class, distinct from Azole or Allylamine antifungals. This agent is characterized by its ability to address a wide range of external biological intrusions. This multi-target action is designed to effectively eliminate the causative agent.


Composition and Physical Forms

The composition of Micolamina relies exclusively on Ciclopirox as the sole therapeutic agent, prepared for Topical administration. Its unique differentiating factor lies in its diverse formulation range, which includes specialized preparations like the film-forming Nail Lacquer (esmalte), alongside conventional cream, gel, and shampoo forms. These forms ensure that the active ingredient is delivered locally and specifically to the affected surface—a characteristic common in dermatological treatments. The use of a specialized Nail Lacquer highlights a focus on targeting intrusions within dense keratin structures.


General Purpose and Mechanism Principle

The general purpose of Micolamina is to halt the proliferation and promote the elimination of problematic external biological intrusions, such as those affecting the skin or nails. This action is achieved because the Ciclopirox molecule functions as a potent chelator, chemically trapping essential metal ions, known as polyvalent cations, that are vital for the target organism's cellular energy production and structural repair. This targeted chemical interference results in a dual-action effect, making the drug both fungistatic (it halts growth) and fungicidal (it kills the organism).

Regulatory References

  1. Ciclopirox Topical Solution Label (DailyMed/NIH)

What side effects are possible with Micolamina?

Possible Side Effects and Safety Information

Adverse Reaction Scope

Category Description based on Regulatory Sources
Key adverse reaction categories Localized application site reactions (e.g., irritation, burning, redness); Hypersensitivity reactions (including contact dermatitis and anaphylaxis); Dermatological effects; Headache (for certain forms).
Frequency classification Common: Application site burning, irritation, pruritus, and erythema. Uncommon: Application site hypersensitivity. Not Known: Anaphylactic reaction (based on post-marketing data).
System-organ classes involved Skin and Subcutaneous Tissue Disorders; General Disorders and Administration Site Conditions; Immune System Disorders; Nervous System Disorders.
Serious adverse reactions Systemic Anaphylactic Reactions are documented as a potential post-marketing event, though classified with an unknown frequency.
Population-specific safety considerations Pediatric Use: Safety is not established below specific age limits that vary by product form. Pregnancy (Category B): Use only if the potential benefit justifies the potential risk. Lactation: Caution is advised as it is not known if the drug is excreted in human milk.
Dose- or exposure-related patterns Local adverse effects may be more common at the start of treatment.
Safety-related restrictions or limitations Contraindicated in individuals with a known history of hypersensitivity to Ciclopirox or its excipients. Not for ophthalmic use (must avoid contact with eyes).

Resulting Safety Structure

  • The official safety profile is dominated by Common adverse effects that are localized to the area of application, consistent with a topical drug.
  • Regulatory documents explicitly classify these local reactions under Skin and Subcutaneous Tissue Disorders and note that these effects may be more noticeable at treatment initiation.
  • A crucial element of the safety profile is the warning regarding Hypersensitivity and the potential for a Not Known frequency Anaphylactic Reaction, placing it under Immune System Disorders.
  • The use is officially restricted by Contraindication in known hypersensitive individuals and includes specific cautions for pediatric patients under certain age limits and during pregnancy/lactation.

The official safety information structures the understanding of risks by establishing that the most frequent events are expected and localized, reflecting the drug's topical administration. However, by classifying the potential for serious Immune System Disorders and placing explicit limitations on use in specific populations (e.g., pediatrics), the regulatory text ensures the overall safety assessment accounts for both common, benign events and rare, systemic risks.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Micolamina

Note: Micolamina is a proprietary entity, and specific, publicly available official documentation detailing its overdose profile from global regulatory bodies (such as the FDA, EMA, or Health Canada) is not available. The information presented below outlines the expected structure of a regulatory overdose section but reflects the absence of specific documented findings.


Documented Overdose Presentations

Official government regulatory documents do not define a specific set of symptoms, signs, or clinical changes associated with Micolamina overdose. No specific physiological systems are officially cited as being affected, nor are specific dose-related or exposure factors defined in regulatory labeling.


Emergency Response and Management

Feature Regulatory Status
Antidote Information No specific antidote or reversal agent is officially documented.
Supportive Management No explicit, officially documented supportive or symptomatic management measures are available.
Immediate Help Required Regulatory documentation does not contain specific, explicit instructions detailing when immediate medical attention must be sought for Micolamina exposure.

Connection to the Overall Overdose Profile

The absence of specific content indicates that the official regulatory profile for Micolamina does not define standard overdose manifestations or management strategies. Patients or caregivers should recognize that any suspected overdose or unusual symptoms following exposure necessitates immediate, professional medical consultation, as the official regulatory guidance is not available to define the specific risks or required emergency actions.

Therapeutic Uses of Micolamina

What Micolamina Treats: Main Uses and Benefits

Treating Superficial Fungal and Yeast Skin Manifestations

Micolamina is commonly used to address a variety of superficial mycoses. This includes common conditions, such as Athlete's foot, Ringworm of the body and groin, Cutaneous Candidiasis, and Tinea Versicolor. The primary therapeutic benefit is to provide symptomatic relief, which may help ease clusters of symptoms that interfere with daily functioning, such as itching, redness, and scaling.

This medication is relevant in clinical settings that involve acute or unstable symptom patterns associated with these conditions.

Supporting Nail Health and Scalp Management

The medication is relevant in clinical contexts involving mild to moderate fungal nail infections (Onychomycosis). Its application supports the management of structural changes in the nail, addressing symptoms such as discoloration and brittleness, and contributes to easing the visual and structural symptoms as the nail grows. Micolamina is also applied in situations involving Seborrheic Dermatitis of the scalp, particularly when supportive symptom management is appropriate. Its use supports the management of the symptomatic burden of flaking, irritation, and redness, which contributes to improved comfort during symptomatic periods.


Quick Fact: Relief for Dermal Discomfort The medication is commonly used to help with symptoms that create noticeable physiological strain, primarily itching and scaling in localized superficial infections. It supports patients during episodes of heightened discomfort by easing the overall symptom load.


Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Micolamina (Ciclopirox) is governed by formal eligibility rules established in government regulatory documents, defining specific populations who can and cannot use the medicine.

Classification Rule (Official Regulatory Status)
Absolute Contraindication Individuals with known hypersensitivity (allergy) to Ciclopirox or any non-active component of the specific formulation must not use this medicine.
Conditional Use (Pregnancy) Classified as Pregnancy Category B. Use is conditional and should occur only if the potential benefit justifies the potential risk to the fetus, due to a lack of adequate human studies.
Conditional Use (Lactation) Use requires caution as it is not known whether the drug is excreted in human milk.

Age-Specific and Comorbidity Restrictions

Eligibility in children varies by product form because safety and effectiveness have not been established below certain ages:

  • Cream/Lotion: Not established in patients below the age of 10 years.
  • Nail Lacquer: Not established in patients below the age of 12 years.
  • Gel/Shampoo: Not established in patients below the age of 16 years.

Use of Micolamina, particularly the Nail Lacquer, is also restricted by patient health status. The product is indicated for immunocompetent patients. Safety and effectiveness have not been studied in individuals who are immunosuppressed (e.g., HIV seropositive, organ transplant recipients) or those with certain conditions like insulin-dependent diabetes mellitus.

What should I know about interactions with other medicines?

Micolamina is an antifungal medication primarily used topically, which generally results in minimal systemic absorption and a lower risk of drug interactions compared to oral antifungal agents. However, patients should still inform their healthcare provider of all current medications, including over-the-counter drugs and herbal supplements, before starting treatment.

Potential Drug-Drug Interactions

The most significant potential interactions for Micolamina (especially the oral or vaginal formulations, but also reported with topical use due to low systemic absorption) involve oral anticoagulants, such as warfarin and related coumarin derivatives (e.g., acenocoumarol, dicoumarol). Micolamina may inhibit the metabolism of these anticoagulants, leading to an increased risk of bleeding by enhancing their effect. Close monitoring of the International Normalized Ratio (INR) is essential if these medicines are used concurrently, and the anticoagulant dosage may require adjustment.

Drug Class Example Agents Potential Interaction
Oral Anticoagulants Warfarin, Acenocoumarol Increased risk of bleeding; enhanced anticoagulant effect.
Other Medications CYP3A4 substrates Possible increased or decreased blood levels of co-administered drugs.

Interactions with Food and Supplements

There are no widely reported clinically significant food interactions with Micolamina. However, some oral antifungals, particularly those metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system, can interact with grapefruit and grapefruit juice, which may inhibit this enzyme. Although Micolamina is primarily topical, patients should discuss dietary concerns with a healthcare professional.

Mechanism of Action

Micolamina, which is formulated with ciclopirox olamine as the active substance, functions through a multi-target mechanism of action, primarily focusing on fungal and other microbial cells. Its interaction is characterized by a high affinity for trivalent metal cations, which influences several intracellular processes. The compound acts as a chelator, binding to metal ions such as iron (Fe^3+) and copper (Cu^3+) that are essential cofactors for various microbial enzymes. This sequestration of metal ions leads to a functional deficiency of critical enzymes, including catalase and peroxidase, which disrupts the cellular defense mechanisms against toxic peroxides and oxidative stress.

Furthermore, its action interferes directly with cellular metabolism by inhibiting essential processes, including DNA replication, DNA repair, and general cellular transport in the target organisms. The cumulative molecular consequences of metal chelation and enzyme inhibition lead to a failure in mitochondrial and metabolic function, culminating in the termination of cell growth and proliferation.

Dosage and Administration Information

How to Use Micolamina — Administration Guidelines

Micolamina (ciclopirox) is a medication strictly for topical use. Adherence to the prescribed administration schedule, route, and technique is essential.

Administration Overview

Feature Official Instruction
Route of Administration Topical only (to the skin, scalp, fingernails, or toenails). Not for oral or ophthalmic use.
Dosing Schedule Varies by formulation: Twice daily for creams/gels; Once daily for nail lacquer; Twice weekly for shampoo for 4 weeks.
Special Conditions Do not use occlusive (air-tight) dressings or wrappings over the treated area.

Procedural Instructions

For Topical Cream/Gel: The product must be gently massaged into the affected skin and the immediately surrounding area, typically in the morning and evening.

For Nail Lacquer: The lacquer is applied once daily (preferably at bedtime) to the affected nail and adjacent skin. A critical procedural step requires the film to be removed completely with alcohol every seven days prior to the next application cycle.

For Shampoo: The shampoo must be lathered and left in place for approximately 3 minutes before rinsing. The schedule dictates a maximum of twice weekly for 4 weeks.

Age-Specific Rules: The use of topical products is restricted to specific age groups, with minimum use ages specified in labeling (e.g., 10 years for dermal products and 12 years for the nail lacquer). Dosage adjustments for specific populations are not typically standardized but must align with approved labeling.

These guidelines define the administration protocol for the medication.

Recent Clinical Evidence

Micolamina: Recent Clinical Evidence

Evidence for Fungal Nail Infections (Onychomycosis)

Research exploring Micolamina was studied for use in fungal nail infections primarily through long-term, randomized controlled trials (RCTs) involving immunocompetent adults with mild to moderate nail involvement. Due to the slow rate of nail growth, observation periods often extended up to 48 weeks. Outcomes examined included mycological clearance and the visual status of the nail. The documentation suggests results apply only to participants who followed the study procedure, which included mandatory professional debridement. The proportion of participants reaching the endpoint of a completely clear nail was infrequent in these trials.

Evidence for Superficial Skin Infections

Research examined Micolamina in short-term, vehicle-controlled clinical trials relevant to conditions such as Athlete's foot and Ringworm. These studies explored changes in clinical status over four to six weeks, combining assessment of fungal eradication with the visual status of the affected skin, including scaling and redness. The data show patterns related to the study's composite endpoint of Therapeutic Success. Evidence is limited in terms of long-term outcomes; research does not provide extensive data on preventing recurrence beyond the initial treatment period.

Evidence for Scalp Manifestations (Seborrheic Dermatitis)

Micolamina was evaluated for scalp manifestations associated with seborrheic dermatitis through randomized, double-blind trials using shampoo or gel formulations. These studies were relevant in assessing short-term symptom patterns in adults. Outcomes were measured using objective scales to monitor changes in the intensity of scaling, inflammation, and patient-reported discomfort. While research highlights measurements showing changes in symptom scores, long-term effects are not fully established, and data on maintenance use are limited.

Overall Research Gaps and Population Focus

The evidence landscape shows a distinct difference in follow-up durations between long-term nail studies and short-term skin/scalp studies. Core clinical research available for Micolamina was focused on the general adult, immunocompetent population. Data are insufficient for certain groups, such as children under 10 years of age, the very elderly, or individuals with concurrent medical conditions. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Ciclopirox Olamine Cream USP, 0.77% (Prescribing Information) - DailyMed (Used for indications and pediatric use limitations)

Frequently Asked Questions (FAQ)

Common questions about Micolamina (FAQ)

Q: Is Micolamina approved for use in children?

Regulatory documents specify different minimum age limits for Micolamina depending on the product form (cream, lacquer, or shampoo). For instance, specific formulations may be restricted to patients aged 10, 12, or 16 and older. Official information indicates that the safety and effectiveness of the product have not been established in patients below these specified ages.

Q: What types of food should be avoided when using Micolamina?

Regulatory sources state that there are no widely reported clinically significant food interactions when using Micolamina, especially since it is a topical medicine applied to the skin or nails. It is common practice that patients review all dietary concerns and the consumption of products like grapefruit with a healthcare professional.

Q: Does Micolamina interact with common painkillers like ibuprofen?

Official regulatory documents specifically highlight significant interactions with certain drug classes, such as oral anticoagulants (like warfarin) and drugs metabolized by the CYP3A4 system. Common, non-prescription painkillers like ibuprofen are not typically included in the official highlighted interaction lists for this topical medication.

Q: Does Micolamina interact with antacids or heartburn medicine?

Regulatory documents detailing specific drug-drug interactions primarily emphasize oral anticoagulants and drugs that affect the CYP3A4 enzyme system. Standard antacids or heartburn medicines are generally not included in the officially highlighted interaction lists for this topical drug, and a review of all medications by a healthcare professional is consistent with product labeling.

Q: Does Micolamina interact with common depression or anxiety medications?

Official product information mentions the potential for interactions with medications that are substrates of the CYP3A4 enzyme system. Since some depression and anxiety medications fall into this category, official information suggests that concurrent use warrants review by a healthcare provider to determine any specific risks.

Q: Does Micolamina affect birth control pills?

Official regulatory documentation does not typically list birth control pills as an interaction for Micolamina. Given that Micolamina is a topical product with minimal systemic absorption, the risk is generally considered low, and official guidance suggests that concurrent medication use warrants review by a healthcare professional.

Q: Why is Micolamina sometimes referred to by a different chemical name?

Micolamina's active agent is known primarily as Ciclopirox. However, official references also frequently use the name Ciclopirox Olamine, which is the specific salt form of the active drug used in many product preparations like creams and shampoos.

Q: How long does Micolamina typically stay in the body after the last dose?

Pharmacokinetic data summarized in regulatory-associated literature indicates that the average half-life for the active ingredient after topical use is short (e.g., less than two hours for one formulation). Most of the compound that is systemically absorbed is typically excreted quickly.

Q: Does Micolamina work better if taken with or without food?

Micolamina is a topical medication strictly for external use on the skin or nails. Because it is not taken by mouth, the timing of its application relative to meals is not a relevant consideration in its administration or efficacy.

Q: What is the main difference between Micolamina and other similar medicines?

Official sources classify Micolamina (Ciclopirox) as a Hydroxypyridone antifungal agent. This classification defines it as chemically distinct from other major drug classes of antifungal medicines, such as the Azoles or Allylamines.

Q: Is it true that Micolamina causes sleepiness?

Regulatory documents list potential side effects by system, including specific categories for Nervous System Disorders. While effects like headache are listed in some product information, sleepiness or sedation is not typically cited as a common or specific adverse reaction for this topical medication.

Q: Can Micolamina impact blood pressure or heart rate?

The official safety profile for topical Micolamina is dominated by localized skin reactions. While some post-marketing reports have included instances of fast, pounding, or irregular heartbeat, this effect is not frequently listed on the regulatory safety profile for the topical forms.

Q: Is Micolamina habit-forming or addictive?

Official classifications identify Micolamina as a synthetic antifungal agent belonging to the Hydroxypyridone class. It is not listed as a controlled substance and official documentation does not indicate any properties that suggest a potential for addiction or habit formation.

Q: Do clinical trials show Micolamina is effective for its main use?

Regulatory approval documents summarize clinical trial findings to establish effectiveness. Efficacy for the indicated conditions was established based on results from randomized controlled studies that measured specific outcomes, such as mycological clearance and clinical response.

Q: How does the time of day affect when Micolamina should be used?

Regulatory instructions for specific formulations, such as the nail lacquer, advise that application should be done once daily, often preferably at bedtime. This timing is recommended to allow the product to remain undisturbed on the treated area for a longer duration.

Q: Is Micolamina available over-the-counter in any country?

Regulatory status summaries from agencies like the FDA and NIH indicate that Micolamina is typically classified as a prescription drug in its various formulations (solution, lacquer, cream, shampoo). The regulatory status of Micolamina as a prescription drug is noted across major governmental health agencies.

Q: Is Micolamina linked to any mood changes?

Regulatory documents classify potential side effects by system-organ class, including Nervous System Disorders. However, specific systemic mood changes, such as new or increased depression or anxiety, are not typically listed as common or frequent adverse reactions for Micolamina.

Q: Can Micolamina be used to prevent a condition, or only to treat it?

Official indications describe Micolamina's primary role in the treatment of specified fungal conditions. However, some formulations, such as the shampoo, are described in related governmental documents as having an anti-seborrheic function that helps prevent the return of related symptoms like scaling.

Q: What is the recommended period of use for Micolamina?

Official regulatory information specifies the total duration of treatment, which varies significantly depending on the product form and the condition being addressed. For example, treatment periods can range from four weeks for certain skin conditions up to 48 weeks or longer for nail lacquer.

Q: What are the rules regarding missed doses of Micolamina?

Regulatory-aligned patient guidance explicitly addresses a missed application, advising the user to apply the dose as soon as the oversight is remembered. This should be done unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Q: Is Micolamina affected by grapefruit juice?

Official interaction documents confirm that there are no widely reported clinically significant food interactions with Micolamina. While grapefruit juice can affect the metabolism of other oral drugs, this is generally not a noted concern for this topical product.

Q: What's the difference between the generic and brand name versions of Micolamina?

Regulatory guidance dictates that the generic version must contain the same active ingredient (Ciclopirox) as the brand name product. Generic versions must also meet the same official standards for strength, quality, and efficacy as their brand-name counterparts.

Q: Are there specific activities or foods to avoid while on Micolamina?

Official regulatory patient guidance provides specific precautions related to the treated area. These can include avoiding the use of other cosmetic products on treated areas or specific advice about wearing clean, dry footwear for certain fungal infections.

How should Micolamina be stored and disposed of?

How to Store and Dispose of Micolamina (Ciclopirox)

Official regulatory information mandates specific conditions for storing and disposing of Micolamina topical forms.


Storage Requirements

Micolamina must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept from freezing and stored away from excessive heat, moisture, and direct light. Due to the flammability of the liquid/lacquer forms, containers must avoid open flame and be kept tightly closed.


Child Safety and Disposal

All preparations must be kept out of the sight and reach of children.

Unused or expired product should not be kept and must be discarded according to official procedures. This is typically done through a medication take-back program or by mixing the product with an undesirable substance before sealing and placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micolamina found in:

A-Z Index: